Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05625659 · ClinicalTrials.gov registry record · NA
Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts
A NA study of Breast Cancer, sponsored by American College of Radiology.
- Recruiting
- Registry status
- NA
- Development phase
- 2,032
- Enrollment target
- 11
- Study locations
NCT05625659: Recruiting NA study of Breast Cancer, sponsored by American College of Radiology.
NCT05625659 is a NA study of Breast Cancer that is actively recruiting participants, run by American College of Radiology. The registered enrollment target is 2,032 participants, below the 2,802-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (27% lower). The trial reports 11 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05625659, a NA study of Breast Cancer, is actively recruiting participants, sponsored by American College of Radiology.
- RECRUITING
- Registry status
- NA
- Development phase
- 2,032 participants
- Enrollment target
- 11
- Study locations
Study Summary
The over-arching goal of the Contrast-Enhanced Spectral Mammography Imaging Screening Trial (CMIST) is to determine if dual-energy contrast-enhanced spectral mammography (CESM) can detect more cancers with fewer false positives than digital breast tomosynthesis (DBT) in women with dense breasts. Aim 1: To evaluate the performance of CESM compared to DBT at baseline for breast-cancer screening in women with dense breasts. Aim 2: To evaluate the performance of CESM compared to DBT at the 1-year follow up for breast-cancer screening in women with dense breasts.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Dual-Energy Contrast-Enhanced Spectral Mammography (CESM)
Study Locations (11)
Florida
- Boca Raton Regional Hospital - Christine E. Lynn Women's Health and Wellness Institute - Boca Raton
- Lake Medical Imaging - The Villages
Alabama
- University of Alabama, Birmingham - Birmingham
Massachusetts
- Boston Breast Diagnostic Center - Wellesley Hills
Michigan
- Henry Ford Health - Detroit
New York
- Memorial Sloan Kettering Cancer Center - New York
North Carolina
- Carolina Breast Imaging Specialists - Greenville
Pennsylvania
- Thomas Jefferson University Hospital - Philadelphia
Texas
- The University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,032 participants |
| Start Date | 2023-03-24 |
| Est. Completion | 2027-07-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05625659
The ClinicalTrials.gov registry entry for NCT05625659 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 2,032 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,802-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (27% lower). The listed sponsor is American College of Radiology, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Dual-Energy Contrast-Enhanced Spectral Mammography (CESM) is the first listed.
NCT05625659 reports 11 study locations spanning 10 distinct geographic areas - top geographies include Florida, Alabama, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05625659 about?
NCT05625659 is a clinical study titled "Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts". The over-arching goal of the Contrast-Enhanced Spectral Mammography Imaging Screening Trial (CMIST) is to determine if dual-energy contrast-enhanced spectral mammography (CESM) can detect more cancers with fewer false positives than digital breast tomosynthesis (DBT) in women with dense breasts. Ai...
What is the current status of trial NCT05625659?
This trial is currently recruiting. It is a NA study. The enrollment target is 2,032 participants. The study started on 2023-03-24. Estimated completion is 2027-07-31.
What conditions does trial NCT05625659 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT05625659?
The interventions under investigation include: Dual-Energy Contrast-Enhanced Spectral Mammography (CESM) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05625659?
This trial is sponsored by American College of Radiology, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05625659 being conducted?
This trial has 11 study locations across Alabama, Florida, Massachusetts, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
-
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
RECRUITING · NA
-
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
RECRUITING · NA
-
A Randomized Controlled Trial (RCT) to Determine the Efficacy of a Multidisciplinary CBT Based Pain Management Program for the Treatment of Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) in Breast Cancer Survivors
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.